Price T Rowe Associates Inc Immunity Bio, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 130,761 shares of IBRX stock, worth $708,724. This represents 0.0% of its overall portfolio holdings.
Number of Shares
130,761
Previous 123,879
5.56%
Holding current value
$708,724
Previous $667,000
24.14%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding IBRX
# of Institutions
212Shares Held
63.3MCall Options Held
1.44MPut Options Held
4.01M-
Vanguard Group Inc Valley Forge, PA13.8MShares$75 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$61.9 Million0.0% of portfolio
-
State Street Corp Boston, MA7.86MShares$42.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.92MShares$21.2 Million0.0% of portfolio
-
Jane Street Group, LLC New York, NY1.72MShares$9.3 Million0.01% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $2.17B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...